Radius Health (“Radius” or “the Company”), a specialty biopharmaceutical company dedicated to bone health and related therapeutic areas, including through its lead product TYMLOS® (abaloparatide) injection, announces that B‑FLEXION Life Sciences has agreed to purchase shares of the Company currently held by affiliates of Patient Square Capital (“Patient Square”) and Webster Equity Partners. B‑FLEXION and Patient Square acquired Radius in August 2022 in a take‑private transaction. “We are proud of the transformation achieved at Radius over the past three years by Scott and his team expanding the impact of an important medicine,” said Jim Momtazee, Managing Partner of Patient Square.
Read the full article: B-FLEXION Life Sciences to Acquire Remaining 57% Interest in Radius Health //
Source: https://www.prnewswire.com/news-releases/b-flexion-life-sciences-to-acquire-remaining-57-interest-in-radius-health-302658260.html